BioSistemika d.o.o. (Slovenia) – Strategic-Technological Analysis
29 pages · PDF · 07 September 2025 · Licensed single-user copy, watermarked to the buyer
Tactical Biotechnology, Human Enhancement & MedTech Synthetic Biology Slovenia
€499 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
BioSistemika d.o.o. is a Slovenian deep-tech company at the intersection of biotechnology and digital innovation. Founded as a spin-off of Slovenia’s National Institute of Biology in 2010, it has evolved from a niche lab software developer into a recognized player in Europe’s bioinformatics and laboratory automation landscape .
The company’s journey reflects the rising importance of biotech and data technology for European strategic autonomy. BioSistemika’s solutions – from smart pipetting aids to cutting-edge DNA data storage – are enabling more efficient laboratories and novel approaches to data management.
Key questions this report answers
- What lab-automation, bioinformatics and DNA-data-storage solutions has BioSistemika developed?
- How has the 2010 National Institute of Biology spin-off matured from lab software to a recognised player?
- Which biotech and data-technology markets and partners does BioSistemika serve in Europe?
- What capability gaps or dependencies affect its role in biotech-driven strategic autonomy?
Inside this report
- Executive Summary
- 1. Corporate Identity & Legal Structure
- 2. Strategic Business Profile
- 3. Technology Portfolio Mapping
- 4. Technology Readiness Assessment
- 5. European Strategic Program Participation
- 6. Academic & Research Origins
- 7. Dual-Use Applications & European Market Strategy
- 8. Strategic Partnerships & European Industrial Alliances
- 9. European Market Focus & Operational Domains
- 10. Intellectual Property & European Innovation Assets
- 11. Leadership & European Technical Expertise
- 12. Capability and Gap Analysis
- 13. Strategic Indicators & European Innovation Metrics
Who it's for
Investors screening BioSistemika d.o.o., competitors and partners assessing their position, and analysts who need a sourced, structured account of the entity and its technology.
Related reports
Methodology, format & delivery
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (07 September 2025). You receive a 29-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.
Related on DFM
More Tactical reports · Biotechnology, Human Enhancement & MedTech · Synthetic Biology · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →